OPEN END TURBO PUT WARRANT - MODERNA | Market Closed - Bid/Ask 15:31:06 2024-06-11 EDT | ||
| 4.52 EUR | -0.22% |
|
| Current month | -9.22% | ||
| 1 month | -38.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 4.52 | -0.22% |
| 24-06-10 | 4.53 | +7.35% |
| 24-06-07 | 4.22 | +6.30% |
| 24-06-06 | 3.97 | +2.06% |
| 24-06-05 | 3.89 | -18.45% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 03:31 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| WKN | UM43NZ |
| ISIN | DE000UM43NZ8 |
| Date issued | 2024-05-07 |
| Strike | 196.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.66 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.43 € |
|---|---|
| Lowest since issue | 2.59 € |
| Spread | 0.02 € |
| Spread % | 0.44% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.6
USD
Average target price
143.9
USD
Spread / Average Target
-3.13%
- Stock Market
- Certificates
- Certificat
